Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
RESEARCH TOOLSreports
Diamedica Therapeutics (DMAC) Stock Price & Analysis
449 Followers
DMAC Stock Chart & Stats
Day’s Range$2.39 - $2.59
52-Week Range― - ―
Previous Close$2.37
Volume21.52K
Average Volume (3M)N/A
Market Cap
$98.75M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 13, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.00Price Target Upside171.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Diamedica Therapeutics News
PremiumCompany Announcements
Diamedica Therapeutics Updates SEC Filing
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Diamedica Therapeutics Inc’s market cap?
Currently, no data Available
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is May 13, 2024 which is in 25 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on Mar 19, 2024. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.14 by $0.02.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -$0.16.
How many shares outstanding does Diamedica Therapeutics Inc have?
Currently, no data Available
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.14. Following the earnings report the stock price went down -1.773%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
---
Diamedica Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (171.34% Upside)
$7.00 (171.34% Upside)
Crowd Wisdom
Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
48.12%
12-Months-Change
Fundamentals
Return on Equity
-46.77%
Trailing 12-Months
Asset Growth
57.46%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
---
DMAC Earnings Call
Q4 2024
0:00 / 0:00
---
DMAC Stock 12 Months Forecast
Average Price Target
$7.00
▲(171.34% Upside)
Technical Analysis
Best Analysts Covering DMAC
1 Year
1 Year Success Rate
7/16 ratings generated profit
1 Year Average Return
+17.18%
reiterated a buy rating 30 days ago
Copying Alexander Nowak's trades and holding each position for 1 Year would result in 43.75% of your transactions generating a profit, with an average return of +17.18% per trade.
---